Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 12, 2009

Spinal Muscular Atrophy Foundation Gives PTC Therapeutics $8.5M

  • The Spinal Muscular Atrophy (SMA) Foundation agreed to fund another round of research at PTC Therapeutics with $8.5 million. This is the second continuation of the collaboration, which began in 2006 to identify and optimize compounds that increase production of the survival motor neuron (SMN) protein; lack of the SMN protein causes SMA.

    Total funding for the initiative is now $11.7 million. The SMA Foundation initiated the partnership with $1.6 million, and in December 2007 it proffered another $1.6 million. Payment of the second tranche was based on certain milestones.

    PTC is using its GEMS (gene expression modulation by small molecules) screening technology, which identifies small molecules that modulate gene expression by targeting the post-transcriptional control processes that act through mRNA molecules.


    Past News for PTC Therapeutics

    Genzyme Jumps on the PTC124 Bandwagon Paying PTC Therapeutics $100M Upfront (July 17, 2008)
    Cystic Fibrosis Foundation Therapeutics Ups Its Funding to $25M for PTC Therapeutics (July 16, 2008)
    Celgene Plugs $20M into PTC Therapeutics (Sept. 13, 2007)
    PTC Therapeutics Granted $15.4M for Duchenne Muscular Dystrophy Research (July 10, 2007)
    Discovery Deal with Pfizer Could Earn PTC $121M in Milestones (Jan. 8, 2007)

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »